DETROIT, July 29, 2013 (GLOBE NEWSWIRE) -- Nano Labs Corp. (OTCQB:CTLE) is pleased to announce that Dr. Victor Castano, Chief Innovations Officer of Nano Labs, will be presenting "Nanotechnology and Photonics: Challenges and Opportunities in Biomedicine" today at the Institute National d'Optique conference in Montreal, Canada.
Dr. Castano will address the challenges facing biomedicine today, in terms of detection techniques, laser therapy, drug delivery and a number of other key problems requiring innovative nanotechnology solutions.
Dr. Castano will present some of the key findings and latest developments the Company has discovered holding promising value in areas including nano-diamonds, luminescent materials, and non-linear optics.
Nanotechnology and nanoparticles are playing an increasingly important role in the development of optics and medicine, including in areas of cancer treatment, drug delivery, pathogen and protein detection, fluorescent labels, DNA-related research and tissue engineering, sorting and purification of biomolecules, and NMR image enhancement.
"Photonics is one of the most exciting and active areas under research and development in the nanotechnology field today," states Dr. Castano. "Nanotechnology is one of the most promising areas to produce novel optic materials for use in biomedicine, due to the ability to tailor new material properties at the molecular level. We are looking at new nanotechnologies for everyday applications that range from the study of optics and biomedicine, to aerospace, and everything in between which makes use of optical materials. Presenting at the INO conference today in Canada, an innovation hub, helps our company to integrate and fast-track the commercialization of our technology to the healthcare industry. We are honored to be partaking in such a prestigious event."
Parties interested in learning more or to receive a copy of the presentation are invited to contact Mr. Bernardo Camacho Chavarria, President Nano Labs.
About INO
A leading technology designer and developer, INO is Canada's largest center for industrial optics and photonics expertise. It is an international leader in its field, having completed over 4,500 R&D contracts to date for Canadian companies across a wide variety of fields. INO has performed 43 technology transfers, and created 27 new high-tech startups. It boasts more than 200 employees, most of them researchers, scientists, and technicians who contribute to INO's international reputation. INO is a private, not-for-profit contract R&D company founded in 1985 by the Canadian and Quebec provincial governments. For more information please visit www.ino.ca.
About Nano Labs
Nano Labs Corp. (CTLE) is a nanotechnology research and development company which began in October 2012, but is able to access resources that encompass nearly 30 years of research and development in nanotechnology as well as hundreds of peer-reviewed and published research papers and other scholarly material. Our Company's research and development team of scientists, designers, and engineers is focused on creating a portfolio of advanced products that could provide benefits to a variety of industries including: (i) consumer products, (ii) energy, (iii) materials, and (iv) healthcare. Through the use and integration of proprietary nano compounds, our goal is to evolve common products into new, revolutionary products in order to make the world a better place. Nano Labs shares are traded on the OTC Bulletin Board in the United States under the ticker CTLE. For more information, please visit www.NanoLabs.us.
The Nano Labs Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16293
Forward looking statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those laws. These forward-looking statements are based upon a number of assumptions and estimates that are subject to significant uncertainties that involve known and unknown risks, many of which are beyond our control and are not guarantees of future performance. Actual outcomes and results could materially differ from what is expressed, implied, or forecasted in any such forward-looking statements and any such difference may be caused by risk factors listed from time to time in the Company's news releases and/or its filings with the OTC Bulletin Board or as a result of other factors.